Henlius (02696.HK): First Patient Dosed in Phase 1 Trial of Trispecific Antibody HLX3902 Targeting STEAP1×CD3×CD28

NewTimeSpace News: Shanghai Henlius Biotech, Inc. (02696.HK) issued a voluntary announcement on July 30, 2026, disclosing that the first patient has been dosed in a Phase 1 clinical study in China for HLX3902 Injection, the Company's self-developed STEAP1×CD3×CD28 trispecific antibody, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumors. The Company also plans to initiate relevant clinical trials in Australia when conditions permit.

The study is an open-label, first-in-human Phase 1a clinical study comprising eight dose levels ranging from 0.005 mg to 1.5 mg, with the primary objectives of evaluating safety and tolerability and determining the maximum tolerated dose (MTD). HLX3902 is designed to simultaneously target STEAP1, CD3, and CD28, enhancing the lysis of tumor cells through T-cell activation. The drug was previously granted clearance to commence Phase 1 clinical trials in Australia in May 2026 and in China in June 2026. As of the announcement date, no trispecific antibody of the same class has been approved for marketing globally.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.